ADGMMEDIUM SIGNALFINANCIAL10-K

ADGM shows improved operational efficiency with reduced losses and lower R&D spending, though coupled with declining cash reserves and increased debt burden.

The company appears to be managing its burn rate more effectively, with operating losses narrowing and R&D expenses declining meaningfully. However, the combination of reduced cash position and increased debt levels suggests potential liquidity pressures that warrant monitoring.

Comparing 2026-03-27 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

ADGM demonstrated improved cost discipline with R&D expenses declining 31% and operating losses narrowing substantially year-over-year. The company's cash position weakened modestly to $17.1M while total debt increased 31% to $21.0M, and stockholders' equity declined to $12.4M. Overall, the financial picture suggests a company working to extend its runway through cost management while facing ongoing funding pressures typical of its development stage.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-50.7%
$71K$35K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
-37.7%
$19.9M$12.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Inventory
Balance Sheet
-34.8%
$2.6M$1.7M

Inventory drawn down 34.8% — strong sell-through or deliberate destocking; watch for supply constraints.

Net Income
P&L
+31.4%
-$36.6M-$25.1M

Net income grew 31.4% — bottom-line growth signals improving overall business health.

R&D Expense
P&L
-30.9%
$15.4M$10.6M

R&D spending cut 30.9% — could signal cost discipline or concerning reduction in innovation investment.

Total Debt
Balance Sheet
+30.9%
$16.1M$21.0M

Debt increased 30.9% — substantial leverage increase; assess whether deployed for growth or covering losses.

Operating Cash Flow
Cash Flow
+25.9%
-$25.7M-$19.0M

Operating cash flow grew 25.9% — strong conversion of earnings to cash, healthy business fundamentals.

Operating Income
P&L
+21.7%
-$27.9M-$21.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Assets
Balance Sheet
-20.8%
$25.3M$20.1M

Current assets declined 20.8% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-16.9%
$20.6M$17.1M

Cash decreased 16.9% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-27
ADDED
As of March 23, 2026, there were 22,210,459 shares of common stock, $0.0001 par value, issued and outstanding.
Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
All statements other than statements of historical facts contained in this Annual Report on Form 10-K including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements.
In some cases, you can identify forward-looking statements because they contain words such as anticipate, believe, contemplate, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will or would or the negative of these words or other similar terms or expressions.
Moreover, we operate in a very competitive and rapidly changing environment.
+7 more — sign up free →
REMOVED
Therefore, the aggregate market value of its common stock held by non-affiliates as of such date cannot be calculated.
The Registrant's common stock began trading on the Nasdaq Capital Market on August 1, 2024.
As of March 21, 2025, there were 15,381,565 shares of common stock, $0.0001 par value, issued and outstanding.
prior to the consummation of the Business Combination (as defined below).
On July 31, 2024, or the Closing Date (as defined below), ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company ( ARYA ), Aja Holdco, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →